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Abstract 
Background.  Health state utility values (HSUVs) are required to calculate quality-adjusted 
life-years (QALYs).  They are frequently derived from generic preference-based measures of 
health.  However, such generic measures may not capture health attributes of relevance to 
specific conditions.  In such cases, a condition-specific preference-based measure (CSPBM) 
may be more appropriate.    
Objective. This systematic review aimed to identify all published accounts of developing 
CSPBMs, to describe and appraise the methods used.  
Method. A systematic search (of Embase, Medline, PsycINFO, Web of Science, the 
Cochrane Library, CINAHL, EconLit, ASSIA and the Health Management Information 
Consortium database) was undertaken to identify published accounts of CSPBM 
development up to July 2015.  Studies were reviewed to investigate the methods used to 
design classification systems, estimate HSUVs, and validate the measures. 
Results. Eighty-six publications were identified, describing 51 CSPBMs.  Around two-thirds 
of these were QALY measures; the remainder were designed for clinical decision-making 
only.  Classification systems for 33 CSPBMs were derived from existing instruments; 18 
were developed de novo.  HSUVs for 34 instruments were estimated using a ‘composite’ 
approach, involving statistical modelling; the remainder used a ‘decomposed’ approach 
based on multi-attribute utility theory.  Half of the papers that described the estimation of 
HSUVs did not report validating their measures. 
Conclusion. Various methods have been used at all stages of CSPBM development.  The 
choice between developing a classification system de novo or from an existing instrument 
may depend on the availability of a suitable existing measure, while the choice between a 
decomposed or composite approach appears to be determined primarily by the purpose for 
which the instrument is designed.  The validation of CSPBMs remains an area for further 
development. 
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Key Points for Decision Makers 
There are two main approaches to developing a classification system (derivation from an 
existing instrument or de novo) and two main approaches to estimating health state utility 
values (using statistical regression or multi-attribute utility theory) for a condition-specific 
preference based measure. 
There is more evidence available to support the validity of classification systems that were 
derived from existing measures of health-related quality of life than there is for classification 
systems developed de novo. 
The choice of methods for the estimation of health state utility values are primarily 
determined by the purpose for which the instrument is being developed and the context in 
which it is to be used. 
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1. Introduction 
The quality-adjusted life-year (QALY) is a measure of health-related quality of life (HRQoL) 
that is frequently used for evaluating the cost effectiveness of healthcare interventions.  
QALYs are calculated by weighting each year of life according to its quality, on a numerical 
scale anchored at 1 (equivalent to full health) and zero (equivalent to being dead), thereby 
combining length and quality of life into a single measure.  These standard “scaling anchors” 
enable comparisons to be drawn between different health conditions [1].  QALY weights are 
frequently sourced from preference-based measures (PBMs) of health-related quality of life.  
PBMs provide a standardised health state classification system and a tariff of quality weights 
for all health states described by the classification system.  Generic PBMs, such as the 
EuroQol EQ-5D [2], Short-Form 6D [3] or Health Utilities Index [4], are commonly used.  In 
addition to enabling the cost-effectiveness of interventions to be compared across a wide 
range of conditions, using the common metric of the QALY, PBMs can also be used to 
inform decision-making at an individual patient-level or between alternative treatments for 
the same condition.  In the latter case, the PBM need not generate QALY weights on the 
scale from dead (zero) to full health (1.00).  Generic PBMs are designed to be applicable for 
all health conditions; however their broad focus has led to some debate around the extent to 
which they capture aspects of HRQoL of particular relevance to specific conditions.  An 
alternative approach is to use a PBM with a health state classification system that is specific 
to a particular condition.  By focusing on the aspects of health that are most relevant to the 
condition of interest, these condition-specific PBMs (CSPBMs) potentially offer greater 
sensitivity and responsiveness [1].   
Here we present a systematic review of the literature describing the development of 
CSPBMs.  The review is structured around the three stages involved in developing a PBM 
[1]. 
The first stage is to construct a classification system consisting of a set of dimensions, each 
of which represents a health attribute.  Each dimension has a number of ordinal levels.  
Health states are constructed by selecting one level from each dimension [5].  The 
classification system must be sufficiently concise to be amenable to valuation, typically 
containing no more than nine dimensions [6].  There are two approaches to developing a 
classification system: constructing a new instrument (de novo) or deriving one from an 
existing HRQoL measure [1].  These existing measures often have large numbers of items 
with several response levels.  In order to produce a classification system that is suitable for 
valuation, the most appropriate single item is selected to represent each dimension, using 
statistical analysis of a dataset that contains the original measure [5].   
Secondly, in order to use the PBM for the calculation of QALYs, a quality weight, or health 
state utility value (HSUV), must be assigned to all the health states described by the 
classification system.  Typically, values are obtained directly for a sample of the health 
states via a valuation survey, in which preferences between different health states are 
elicited either from a sample of people with the condition or from a sample of the general 
population.  Preference elicitation techniques include the standard gamble (SG), time trade-
off (TTO), visual analogue scales (VAS) and discrete choice experiments (DCEs).  One of 
two modelling methods is then used to estimate HSUVs for all health states described by the 
classification system [6].  The first of these is described as the ‘composite’ approach 
because valuations are obtained simultaneously for dimensions and dimension-levels.  
Regression models are estimated, in which the dependent variable is the observed HSUV 
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and the independent variables are binary dummy variables representing each level of each 
dimension.  Various criteria can be used to compare the performance of alternative models, 
enabling a preferred model to be selected.  The second method is described as 
‘decomposed’ because dimensions and dimension-levels are valued separately and the 
results are combined in the modelling phase [5].  In the valuation survey, respondents 
consider each dimension in isolation and scale the levels of the dimension relative to one 
another and, in a separate exercise, consider the relative importance, or weighting, of each 
dimension.  HSUVs are estimated by solving a series of equations based on multi-attribute 
utility theory, using the results of the valuation survey. 
Finally, the new PBM should be validated.  Brazier et al [1] recommend assessing the 
convergent validity between the CSPBM and generic PBMs, and comparing them in terms of 
their discriminative validity and responsiveness.  This enables an estimation of the impact on 
the results of cost effectiveness analyses of using the CSPBM rather than a generic 
alternative and indicates whether the CSPBM is better able to capture differences and 
changes in HRQoL and condition severity.  Where the descriptive system has been derived 
from an existing measure, they suggest that the magnitude of the information lost in the 
process of reducing the number of items should be estimated, by assessing the convergent 
validity between the CSPBM and its parent measure and by comparing them in terms of their 
discriminative validity, responsiveness and convergent validity with other relevant measures.   
Four previous systematic literature reviews have been undertaken to address research 
questions that relate to or include the development of CSPBMs.  Mortimer and Segal [7] 
aimed to compare four methods for estimating QALY weights from non-PBMs, including 
derivation of a PBM from an existing measure, and to determine what effect the choice of 
method may have on the values generated.  Their review included generic and condition-
specific measures.  Petrillo and Cairns [8] aimed to identify best practice in mapping from 
condition-specific non-PBMs to generic PBMs and in developing CSPBMs from existing 
measures.  Lin et al [9] compared the content of CSPBMs and mapping studies with the EQ-
5D in order to identify health attributes for which additional, ‘bolt-on’ dimensions to the EQ-
5D may be appropriate.  These three reviews did not focus solely on the development of 
CSPBMs, therefore their search terms were not specifically designed for this purpose, and 
discussion of the CSPBMs and the methods employed in their development were 
necessarily brief or absent.  None of these reviews included studies in which the 
classification system was developed de novo.  Another systematic review, undertaken by 
Brazier at al [1], focused solely on the methods for the development of CSPBMs, both de 
novo and from existing instruments.  Their literature search identified 26 papers describing 
the development of 22 instruments up to December 2010.  A number of other CSPBMs have 
been developed since this review.  An informal review of the titles, abstracts and keywords 
of several papers describing the development of CSPBMs suggested that a search strategy 
incorporating a wider range of search terms could potentially identify additional papers.   
Here we present a systematic review based on a more recent and comprehensive search 
strategy, with a clear focus on identifying papers that describe the development of a 
CSPBM.  The aim of this review is to identify and appraise the methods used to develop 
these measures.   
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2. Methods 
A search strategy was developed, based on four groups of terms: 
1. to identify papers describing the development of instruments 
2. to limit the search to studies in which HSUVs were elicited to estimate a PBM 
(excluding those in which health states were valued for other purposes) 
3. to identify papers discussing the measurement of HRQoL 
4. to identify preference based (rather than non-preference based) instruments. 
The following databases were searched: Embase, Medline, PsycINFO, Web of Science, the 
Cochrane Library, CINAHL, EconLit, ASSIA and the Health Management Information 
Consortium (HMIC) database.  In addition, citation searching, a Google search and searches 
of the Discussion Papers published on the Sheffield School of Health and Related Research 
(ScHARR) Health Economics and Decision Science website were undertaken.  An example 
search strategy and full details of the databases searched are presented as supplementary 
material.     
The review includes papers that: 
 relate to an instrument that is designed for a single named condition or a related 
group of conditions (eg multiple sclerosis or neurological conditions, glaucoma or 
visual impairment); 
 and relate to an instrument that provides a classification system, based on HRQoL, 
functioning or symptoms, which is capable of categorising all patients with the 
condition; 
 and relate to an instrument for which an algorithm has been developed to enable 
preference weights to be calculated for all health states defined by the classification 
system, or where the intention to develop such an algorithm has explicitly been 
stated; 
 and provide an account of the development or validation of such an instrument, 
whether all or part of the development process, including revaluations of existing 
instruments using a different population; 
 or review various CSPBMs. 
The review excludes papers that: 
 use demographic or other factors, either alone or in combination with items drawn 
from HRQoL questionnaires, to predict utility; 
 or are not written in English;  
 or are commentaries, editorials, letters, conference abstracts or dissertations; 
 or provide an account of health state valuation if this does not form part of the 
development of a CSPBM; 
 or concern the development of a bolt-on dimension to an existing generic measure. 
The original search was undertaken in July 2011 and was repeated in July 2013 and July 
2015.  In total, the searches produced 11,706 results (including some duplicates due to 
slight overlaps between the dates covered by the searches).  Titles and abstracts were 
assessed independently by two reviewers in order to exclude any papers that were not 
relevant to the review.  Through cross-referencing and discussion, both reviewers agreed on 
a shortlist of potential studies for inclusion.  Conference or dissertations abstracts or project 
records for which the full text was not available were excluded (the reviewers included full-
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text manuscripts corresponding to two conference abstracts, in the form of two papers that 
had been accepted for publication).  The full text of the remaining papers was obtained for 
assessment against the inclusion and exclusion criteria.  In total, across the three literature 
searches, this resulted in the identification of 86 papers, covering the development of 51 
instruments (Figure 1).  Assessment of the papers against the inclusion and exclusion 
criteria was undertaken independently by both authors and no disagreements arose.  
Data were extracted using a data extraction form structured around the process for 
developing a PBM (please see supplementary material). 
Fig. 1 Literature search results 
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3. Results 
3.1 Overview of the literature 
The literature search yielded 86 publications that met the inclusion criteria for the review, 
including the four previous reviews outlined above (see Figure 1).  The remainder described 
the development of 51 different CSPBMs, including two classification systems that were yet 
to be valued.  Some authors reported the entire process of developing a measure in a single 
paper, while others reported the development of the classification system and the estimation 
of the tariff separately.   Table 1 links the papers that discuss the development of each 
measure, and summarises some of the key features of the CSPBMs, as discussed below. 
As outlined above, PBMs can be used in cost effectiveness analyses to inform resource 
allocation across the healthcare system, by generating the HSUVs required for the 
calculation of QALYs, and can also be used to inform decision analysis at an individual or 
clinical level.  Only around two-thirds of the identified studies aimed to produce an 
instrument capable of generating QALY weights.  The remainder produced an instrument 
purely for individual or clinical-level decision-making, and stated that their measures were 
not designed to generate QALY.  These studies aimed to identify the factors that influence 
patients’ experiences of living with disease and that inform patients’ and clinicians’ decisions 
with respect to treatment alternatives, to quantify the relative importance of these factors, 
and to produce instruments capable of informing resource allocation within the condition of 
interest from a patient perspective. 
Common areas for CSPBM development were cancer (eight instruments), urinary, 
gynaecological and sexual health issues (eight), respiratory conditions (seven), neurological 
conditions (seven), mental health or cognitive deficits (five), vision (three) and oral health 
(two).  A third of the classification systems focused solely on specific symptoms without 
considering wider impacts on HRQoL.  The majority (62.7%) had between four and six 
dimensions and the total number of health states ranged from nine to several million.  Nearly 
half of the studies were UK-based and around one fifth were undertaken in the USA.  Three 
different sets of scaling anchors were used: perfect health and being dead, the best health 
state described by the classification system and being dead, and the best and worst health 
states described by the classification system.  Only two studies [11; 42] produced tariffs that 
included negative values. 
The classification systems for 33 of the CSPBMs were derived from existing non-PBMs; 18 
were developed de novo. 
Table 1 
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3.2 Methods for the development of classification systems 
3.2.1 Derivation from an existing instrument 
Table 2 presents the methods employed by studies that derived a classification system from 
an existing measure.  The main reasons provided for selecting a particular instrument as the 
basis for a CSPBM were wide usage in clinical and research settings, psychometric 
properties, suitability for a range of condition subtypes or severity levels, and coverage of 
dimensions considered important by patients.  One study [22] based their choice on a 
systematic comparison of available HRQoL measures. 
Twelve of the 33 classification systems that were derived from an existing instrument 
adopted the ‘health state classification approach’ developed by Brazier et al [1], which 
employs statistical techniques to determine the dimensional structure of an instrument, 
followed by a combination of traditional psychometric analysis with one of the “new” 
psychometric techniques (Rasch analysis or item response theory) to select one item to 
represent each dimension.  Rasch analysis is based on the idea that there is a latent scale 
for the construct being measured (in this case, HRQoL), on which both respondents and 
item response levels are located.  The probability that a respondent will give a particular 
response to a particular question is calculated as a logistic function of the distance between 
the position of the respondent and the position of that response level on the latent (logit) 
scale.  Rasch models can be used to analyse the psychometric properties of existing scales 
and develop new scales [92; 93] and offer a number of advantages compared to traditional 
psychometric techniques1 [94].    
In the health state classification approach, item selection takes place in two phases.  In the 
item elimination phase, Rasch analysis is typically employed to identify and adjust items 
where respondents struggle to distinguish between response levels (disordered thresholds) 
and items that behave differently between different subgroups of respondents (differential 
item functioning).  Items are removed if they exhibit poor fit to the Rasch model, using item 
chi-squared statistics, item fit residuals and measures of model goodness of fit (the item-trait 
interaction chi-squared statistic, mean fit residuals and the person separation index).  Only 
the remaining, unadjusted items are considered during the item selection phase.  Item 
selection typically uses both new and traditional psychometric methods to compare items.  
Rasch analysis is used to assess the extent to which item-levels cover the full range of 
condition severity (ie their spread across the latent scale).  All studies also considered how 
well items fitted the Rasch model.  The psychometric criteria employed to compare items 
included acceptability (missing data), item difficulty (item response distributions), the extent 
to which the item measures the intended construct (internal consistency) and sensitivity to 
change (responsiveness).  Several (n = 5) of the studies that took this approach employed 
expert opinion to enhance content validity and clinical relevance and to avoid redundancy.   
Brazier et al [1] also recommend exploring whether the number of item response levels can 
be reduced, using Rasch analysis and response frequencies; only one of these studies [71] 
did not do so. 
                                                
1 Unlike traditional psychometric approaches, Rasch models produce interval scales, which are based 
on an estimate of the true score rather than relying on observed scores.  Item parameters are 
estimated independently of the sample used for scale construction; similarly, person values are 
estimated independently of the items used.  This avoids two limitations of traditional psychometric 
methods, in which results for scales are sample dependent and vice versa.  Rasch models are more 
tolerant of missing data and do not require imputation of missing values [94]. 
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The remaining studies adopted a variety of methods, primarily psychometric criteria and 
expert opinion, to determine dimensions and select items.  In five studies, individual items 
were not selected to represent each dimension; instead, item responses were summed to 
produce overall dimension scores or new response levels were assigned to each dimension.   
Table 2 
 
3.2.2 Developing a classification system de novo 
The methods used for developing a classification system de novo are summarised in Table 
3.  All but four studies used qualitative work with patients at some stage of the process.  Six 
studies took an inductive approach to determining the domains to be included in their 
classification systems, constructing dimensions by analysing data from interviews with 
patients and clinicians [10; 21; 27; 75; 76; 77].  Others used a combination of statistical, 
qualitative and literature-based techniques.  A wide variety of methods were employed to 
construct and select items to represent each dimension, although relatively few studies 
reported using psychometric techniques [41; 48; 63; 76; 77].  Rather than developing items, 
eight studies constructed intra-domain statements to describe the severity levels for each 
dimension from analysis of qualitative interviews with patients [10; 14; 21; 24; 27; 75] or 
expert opinion [16; 24; 74]. 
Table 3 
3.2.3 Validation 
Thirty-six of the 51 classification systems were not validated.  Six of the studies that derived 
their CSPBM from an existing measure repeated the process on a separate dataset and 
compared the results, as recommended by Brazier et al [1].  Other studies undertook a 
separate survey to test the psychometric properties of the classification system (including 
test-retest reliability; convergent validity with PBMs, HRQoL measures and clinical 
measures; discriminative validity; responsiveness; and unidimensionality).  Other methods 
involved further analysis of the dataset used to develop the classification system, using 
Rasch tests of unidimensionality and item redundancy [45; 57] or psychometric criteria [17], 
or constructing a temporary scoring index and assessing the performance of the regression 
model and the psychometric properties of the values generated [41].   
One vision-specific classification system [48] was validated independently by two 
subsequent publications [50; 52], which described the translation of the instrument into other 
languages. 
 
3.3 Preference elicitation techniques 
Table 4 summarises the methods used to select health states and to elicit preferences.  
Thirty-two studies elicited preferences from a sample of the general population, 21 elicited 
preferences from people with the condition and one surveyed clinicians.  With the exception 
of one paper that did not explicitly mention QALYs [17], all studies that obtained valuations 
from the general public aimed to produce an instrument capable of producing QALY weights.  
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Eighteen of the 21 studies that obtained valuations from patients developed non-QALY 
measures.   
 
3.3.1 Composite approach 
A composite approach was adopted to estimate the tariffs for 34 classification systems.  Two 
additional studies estimated a new tariff for an existing classification system [31; 71] using a 
different population [32; 72].  Three papers [16; 59; 64] undertook more than one valuation 
of the same classification system, aiming to compare the tariffs obtained via different 
methods.  
Five classification systems were small enough for preferences to be elicited directly for all 
health states from all survey respondents.  Among the others, the dominant methodology 
was to obtain valuations for health states prospectively sampled from the classification 
system.  Samples of health states were selected from most classification systems using a 
statistically efficient design, such as an orthogonal array [95].  The number of conceptual 
dimensions represented by three classification systems [23; 45; 87] exceeded the number of 
statistically distinct dimensions, increasing the likelihood of interdependencies between 
items, and hence the possibility of a statistical design including implausible combinations of 
dimension levels.  Therefore, these studies employed a ‘Rasch vignette approach’, which 
uses Rasch analysis to identify health states typically reported by people experiencing 
different levels of condition severity.  This ensures that the sample contains health states 
that are likely to be experienced by people with the condition.  Two studies [23; 35] involved 
people with the condition described by the health states to ensure that the selected states 
were plausible.  All but four of these studies aimed to produce a QALY measure, several of 
which stated that they selected their valuation technique in order to enhance comparability 
with the EQ-5D or to comply with guidelines [96] issued by the UK National Institute for 
Health and Care Excellence (NICE) [23; 30; 42; 46; 47; 57; 61; 82; 84; 87; 89].  Three 
studies selected DCE methods to produce non-QALY instruments to inform decision 
analysis, stating that DCEs mirror the ways in which patients choose between treatment 
strategies [25; 28] or are more appropriate than SG or TTO approaches for chronic 
conditions where death is not a likely outcome [14].  The latter also provided a rationale for 
using DCEs to elicit preferences for a QALY measure [24]. 
An alternative methodology, used in three studies that aimed to produce non-QALY 
instruments for decision analysis, was to ask people with the condition to complete the 
classification system, thereby reporting the health state they were currently experiencing, 
and then to complete a preference elicitation exercise for their own current health [18; 44; 
62].  The values provided for the respondents’ own health states were used in regression 
analysis to obtain HSUVs for all health states described by the classification system. 
 
3.3.2 Decomposed approach 
Tariffs for 15 classification systems were estimated using a decomposed approach.  In 
addition, two studies [66; 69] estimated new tariffs for two existing classification systems [65; 
68] in different populations.  The sample of health states required to estimate a decomposed 
model is largely determined by multi-attribute utility theory.  Values for dimension-levels are 
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obtained using ‘single attribute states’: respondents are asked to consider each dimension in 
isolation and to scale the levels of the dimension relative to one another.  The relative 
weighting of each dimension is assessed using its ‘corner state’, in which the relevant 
dimension is at its worst level and all others are at their best levels.  Finally, respondents 
value a number of ‘multi-attribute states’ to estimate the power function required to convert 
VAS values into utility scores [97].  The most common technique was to value all single 
attribute states, all corner states and a small number of multi-attribute states using VAS and 
to value the corner states and multi-attribute states using a choice-based method.  Two 
studies omitted a corner state that was considered implausible [15; 63].  Four studies [15; 
49; 54; 63] included fewer than the three multi-attribute states required for the multiplicative 
multi-attribute utility function that they used to predict HSUVs [5].  Six studies provided a 
rationale for their choice of methods: minimising respondent burden [39; 49], consistency 
with economic theory and theoretical suitability [38], or replicating the methods of previous 
studies [17; 66; 69; 81].   
An alternative technique did not involve the valuation of health states.  Instead, respondents 
were asked to weight dimensions relative to each other, then to score the levels of each 
dimension independently of the others, using resource allocation tasks and VAS [10; 21; 27; 
75].   
Table 4 
3.4 Modelling techniques 
Table 5 presents details of 32 composite models selected to produce tariffs for 28 
classification systems, plus five models reported by one study that did not select a preferred 
specification [64].  Of the remaining classification systems that were valued using a 
composite approach, four did not require models because all health states were valued 
directly [33; 59; 76; 79].  One study that obtained direct valuations for all health states 
estimated models to predict values for members of the population outside the study sample 
[16].  One study did not provide details of their model [78].  The majority of models (n = 26) 
used either an ordinary least squares (OLS) or random effects (RE) specification.  The five 
models based on the results of DCEs were estimated using RE probit or conditional logistic 
regression.  A greater likelihood of interactions between items was anticipated by the 
developers of three classification systems in which the dimensions were highly 
correlated[46; 35; 87].  These studies used OLS regression models to examine the 
relationship between mean observed HSUVs and values on the Rasch logit scale 
corresponding to the health states that were directly valued.   
In 14 studies, some model coefficients were found to be inconsistent with the expected 
direction of preferences.  In three of these studies, the final models included inconsistent 
coefficients [12; 64; 71]; the remainder merged inconsistent coefficients to produce a 
consistent model.  Twelve studies tested the inclusion of preference interactions.  Eight 
studies employed dummy variables to capture the effect of any dimension being at its 
highest or lowest level [12; 13], any dimension being at its most severe level [23; 55; 61; 72], 
any dimension being at least level 3 or at least level 4 [72] or two or more dimensions being 
at level 4 or 5 [84; 89].  Two studies fitted first-order interaction terms [44; 72] and three did 
not describe their interaction terms [16; 57; 71].  Only two studies included an interaction 
term in their preferred model [61; 72].   
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There are two reasons for evaluating the performance of models: to select the preferred 
model and to assess the quality of the preferred model.  The following summary concerns 
preferred models only.  Given that these models aim to predict values for health states, an 
important test is the difference between observed and predicted values for the health states 
that were directly valued.  The majority of studies assessed this using the mean absolute 
error (n = 20); some also reported the number of health states with prediction errors > 0.1 or 
> 0.05 (n = 11).  Most studies reported the number of inconsistent coefficients (n = 27) and 
the number of significant coefficients (n = 25).  These tests can be calculated for any model 
specification, making them useful for comparisons between alternative models [5].  A 
number of other statistics were reported, including R-squared or R-squared type statistics, 
root mean squared error, the Akaike information criterion, the Bayesian information criterion, 
the Ljung-Box statistic and the Jarque-Bera test of normality of prediction errors.  Two 
papers reported no model performance statistics [25; 28].  Only two models that were 
selected to produce a tariff included inconsistent coefficients, although 11 of the preferred 
models included levels that had been merged to remove inconsistencies.  In 19 of the 25 
models for which this was reported, at least 80% of coefficients were significant (p < 0.05).  
MAEs ranged from 0.008 to 0.065.  With the exception of two models [13; 60], the 
percentage of health states with prediction errors greater than 0.05 ranged from 31% to 
44%, while the percentage of errors greater than 0.1 varied from 2% to 16%. 
In addition to the models listed in Table 5, two studies produced alternative tariffs for existing 
instruments.  Kharroubi et al [86] estimated new models for two existing measures [84; 89] 
using non-parametric Bayesian methods in order to address certain limitations of the 
standard approach, in terms of the size and pattern of prediction errors and the extent to 
which the effects of covariates are captured.  Hernandez-Alava et al [90] rescaled six PBMs, 
including the AQL-5D [89], onto a common scale, using ranking data. 
 
Table 5 
The 13 studies that directly valued individual health states to inform a decomposed model 
transformed the values obtained from the VAS into SG or TTO utilities prior to fitting the 
MAU function, using a power curve or function.  The multiplicative functional form proved the 
dominant model due to its ability to allow for some preference interactions between 
dimensions; one study found that additive models were adequate to estimate tariffs for two 
of their three population subsamples, but required a multiplicative model for their third 
subsample and their combined tariff [66].  Only five of these studies reported performance 
statistics to illustrate the predictive ability of their models [11; 17; 39; 69; 81]. 
All four studies in which dimensions and dimension-levels were valued separately used an 
additive MAU functional form, which allows for no preference interactions between 
dimensions.  None of these studies assessed the predictive ability of their models. 
 
3.5 Validation methods 
Methods for the validation of CSPBMs are illustrated in Table 6 and discussed here in 
relation to recommendations made by Brazier et al [1].  Twenty-one studies assessed the 
convergent validity of their measures: four compared the CSPBM with the measure from 
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which it had been derived; eight compared it with other PBMs.  Eighteen studies undertook 
an evaluation of discriminative validity, although only three compared this with another 
measure: two with the EQ-5D and one with the EQ-5D, SF-6D and the parent measure.  
Responsiveness was considered by eight studies, of which only two compared the 
responsiveness of the CSPBM with another measure.  Around half of the papers that 
described the estimation of a tariff for one or more CSPBMs did not report any validation of 
their measure(s).   
Ten CSPBMs were validated retrospectively in subsequent publications [19; 20; 36; 40; 50-
53; 67; 73; 85; 91].  These adopted a range of methods, including comparisons with 
algorithms that map from the parent measure of the CSPBM to EQ-5D values.  Brazier et al 
[1] conducted retrospective validations of four instruments [46; 71; 84; 89] following their own 
recommended procedure. 
Table 6 
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4. Discussion 
4.1 Methods for developing a classification system 
Two methodological frameworks for the development of classification systems have been 
proposed: one for the derivation of classification systems from existing measures [1] and one 
for the development of classification systems de novo [77].   
 
4.1.1 Derivation from existing instruments 
Brazier and colleagues have developed the ‘health-state classification approach’, which 
provides a guide to the methods for deriving a classification system from an existing HRQoL 
measure, while minimising the loss of descriptive information and enabling HSUVs to be 
estimated from responses to the original measure [1].  The majority of papers describing the 
derivation of a CSPBM from an existing measure that had been published since 2009 used 
this approach, although relatively few followed its recommendations for validation.  This 
suggests that the health state classification approach is emerging as the dominant method 
for deriving a classification system from an existing measure.  Differences were apparent 
between these studies; however, this approach is intended as a guide that should be 
adapted to each particular application, rather than a rigid methodological process.   
Across all studies in which individual items were selected from the original measure, all but 
one [79] used traditional psychometric criteria, Rasch analysis or factor analysis to do so.  
Given the strong emphasis that the health-state classification approach places on new 
psychometric techniques, it is unsurprising that the use of Rasch analysis has increased 
substantially in recent years.  Expert opinion retains a significant role at various points in the 
process, illustrating that however robust the statistical methods may be, it remains important 
to check that their results make clinical sense.   
Among those studies that used an existing instrument as the basis for a CSPBM, only one 
[22] reported undertaking a systematic comparison between candidate measures to provide 
a robust justification for selection of a particular instrument, suggesting that this could be a 
fruitful area for future research. 
Deriving a classification system from an existing measure may increase the scope for the 
PBM to be adopted in cost-effectiveness studies. The PBM can be applied to existing 
datasets that contain the original measure, enabling retrospective economic evaluations to 
be undertaken.  Furthermore, selecting an instrument that is well accepted by relevant 
clinical and research communities may enhance the acceptability of the PBM.  However, 
HRQoL measures were not intended for this purpose and not all will provide a suitable basis 
for a PBM [5]. Where no suitable measure is available, the classification system will have to 
be developed de novo [1].  
 
4.1.2 Development de novo 
Stevens and Palfreyman [77] have recommended a best practice method for developing a 
classification system de novo, in which dimensions and items are derived inductively from 
analysis of qualitative interviews with patients or the public.  One third of the de novo studies 
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employed this approach [10; 21; 27; 75; 76; 77], although the majority of studies involved 
people with the relevant health condition at some stage.  
Notwithstanding their recommendations for a ‘bottom-up’, qualitative approach, it is notable 
that Stevens and Palfreyman made extensive use of new and traditional psychometric 
methods when selecting items for their classification system [78].  Given that classification 
systems are intended for use as questionnaires to be completed by people with the relevant 
condition, one may expect developers to use similar methods to those used in the 
construction of non-preference based HRQoL measures.  This typically involves analysis of 
a dataset containing a draft version of the classification system, using either new or 
traditional psychometric techniques, in combination with insights derived from patients, 
clinical experts or the relevant literature [1].  However, only six of the 18 de novo studies 
reported that they had evaluated the psychometric properties of items in the development 
[41; 48; 63; 76; 77] or validation [41; 63; 74] of their classification systems.  This limits the 
range of evidence available to support the validity of many classification systems that were 
developed de novo, particularly compared to those derived from existing instruments, the 
majority of which employed psychometric techniques to select items.  
 
4.2 Methods for generating a tariff 
Context appears to be an important factor in the selection of methods for estimating HSUVs 
for a CSPBM.  As we have seen, most studies that designed non-QALY instruments for 
decision analysis in condition-specific settings elicited preferences from patients and used a 
decomposed approach, which explicitly weights dimensions relative to one another, arguably 
providing a more appropriate method for identifying the factors of greatest importance to 
patients.  Conversely, the requirements of national decision-making bodies were a key 
determinant of the methods adopted by studies that aimed to produce a QALY measure; for 
example, the UK studies tended to follow NICE guidance, which stipulates that tariffs should 
be statistically modelled from societal preferences, elicited using the Measurement and 
Valuation of Health variant of the TTO technique [96].  The importance of context is 
supported by the predominance of QALY measures developed in settings which rely on 
QALY-based frameworks to inform resource allocation for the healthcare system overall, in 
contrast to the predominance of non-QALY based decision analysis tools in the US setting, 
where patients pay for medical treatment either directly or via insurance, leading to a greater 
focus on patients’ perceptions of health status and treatment outcomes. 
Dolan [98] has argued that methodological considerations may determine the choice 
between decomposed and composite approaches.  The extent to which this is reflected in 
the approaches adopted by the included studies is mixed.  Firstly, as the size of the 
classification system increases, so does the size of the sample of health states required to 
estimate a composite model, whereas the number of states required for a decomposed 
model remains constant.  Dolan suggests, therefore, that the decomposed approach may be 
better suited to larger classification systems.  This appears to be reflected in the included 
studies: six of the 34 classification systems that were valued using a composite approach 
described more than 10,000 health states, compared to nine of the 15 that were valued 
using the decomposed approach (Tables 1 and 4).  Secondly, he asserts that the 
decomposed approach may be less appropriate for classification systems that include 
correlated dimensions, due to the restrictions it places on preference interactions between 
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dimensions and its requirement to obtain valuations for potentially implausible corner states 
[97].  The findings of this review do not indicate that the potential for interactions between 
dimensions influenced the choice of approach.  Most of those that followed a decomposed 
strategy allowed for limited preference interactions by fitting multiplicative models to their 
data, whereas only four that followed a composite strategy specifically avoided selecting 
implausible states and only two found that an interaction term improved the predictive ability 
of their model (indeed, most did not report testing for preference interactions).  A further 
implication of dimension orthogonality is that dimensions defined according to specific 
symptoms are more likely to be structurally independent than dimensions that reflect broader 
impacts on HRQoL.  This indicates that a composite strategy may be better suited to 
classification systems that describe the impact of the condition on HRQoL.  There is some 
evidence that the included studies followed this pattern.  As Table 1 shows, 17 classification 
systems did not include dimensions that describe the impact of the condition on aspects of 
people’s HRQoL, focusing instead on describing symptoms of the condition.  Twenty-three of 
the 34 classification systems that were valued using a composite approach included HRQoL 
attributes, compared to six of the 15 that were valued using the decomposed approach. 
It has been suggested that the decomposed approach provides a stronger theoretical 
foundation due to its basis in MAU theory.  Dolan [98] asserts that this theoretical advantage 
is largely irrelevant if it does not enhance the ability to predict HSUVs.  One of the included 
studies [61] estimated both a composite and a decomposed algorithm for the same 
classification system, concluding that the algorithms performed similarly well in terms of 
responsiveness and discriminative validity.  Following their review of the methods for 
converting condition-specific measures into PBMs, Petrillo and Cairns [8] found no evidence 
to prefer either a composite or a decomposed approach. 
Among the studies that took a composite approach, model selection was generally based on 
the difference between observed and predicted values, the proportion of coefficients that 
were consistent and the proportion of coefficients that were significant.  The performance of 
the preferred models varied considerably.  Few of the studies that took a decomposed 
approach reported performance statistics to illustrate the predictive ability of their models (n 
= 5). 
Young et al [87] and Mavranezouli et al [45; 46] developed novel approaches to valuation 
and modelling based on Rasch analysis.  While most studies adopted statistically efficient 
designs to select health states for inclusion in the valuation survey, these authors noted that 
such designs may generate implausible health states when applied to classification systems 
with interdependent dimensions.  This led to the development of the Rasch vignette 
approach, which provides a method for selecting health states based on the combinations of 
item-levels that are most likely to be experienced by people with the condition.  Rather than 
using individual dimension-levels as the independent variables in the regression analysis, 
these studies used corresponding Rasch logit values for health states to predict HSUVs.  
Two subsequent studies have used similar techniques to select a sample of health states 
[23] or predict HSUVs [35].  Although there remain some issues to resolve, particularly the 
ability of the technique to predict values for individual health states rather than groups of 
states based on total dimension-level scores [23], this is a promising new approach that is 
an important area for further research.  
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4.3 Validation methods 
Brazier et al [1] recommend that the validity and responsiveness of the CSPBM should be 
assessed in comparison with generic PBMs and (where appropriate) the parent measure.  
However, relatively few papers reported a thorough validation of their measure.  It is worth 
noting that a number of validations were reported in subsequent papers, therefore 
validations of some instruments may be reported in future publications.  Where validation 
was undertaken, this seldom adhered to these best practice methods.  Convergent and 
discriminative validity were reasonably well covered, responsiveness less so, possibly due to 
a lack of access to longitudinal data. 
 
4.4 Tariffs and values 
In order for the results of CSPBMs to be used to calculate QALYs, the valuations for health 
states described by the CSPBM should lie on a scale from full health (one) to being dead 
(zero) [1].  All instruments with values anchored against the worst and best possible health 
states were designed for decision analysis only, not for estimating QALYs.  Among those 
studies that sought to develop a QALY measure, all anchored the state of being dead at 
zero.  Eighteen selected an upper anchor of generic full health, while twelve used an upper 
anchor of condition-specific full health (the best health state described by the classification 
system).  The definition of ‘full health’ is a subject of debate in the literature.  Condition-
specific full health is not necessarily equivalent to perfect health.  Respondents to a 
valuation survey may assume that patients in the best possible health state may have 
decrements on dimensions that are not included in the classification system, due to the 
condition itself or due to co-morbidities [99].  Brazier et al [1] assert that comparability is 
problematic between instruments that do not share a common upper anchor; therefore 
PBMs should be anchored against death and generic full health rather than the best possible 
health state.   
Only two of the condition-specific tariffs included negative HSUVs [11; 42], despite the fact 
that several instruments were developed for conditions that cause severe decrements in 
HRQoL.  One hypothesis is that the relatively narrow coverage of HRQoL attributes by 
condition-specific classification systems compared to the EQ-5D allows valuation survey 
respondents to assume high levels of function on other HRQoL attributes [1].  However, it is 
notable that another popular generic PBM, the SF-6D, also has no negative values [3].  
Further research is required to understand this phenomenon. 
 
4.5 Conclusion 
This paper presents a detailed systematic review of the literature describing the 
development of CSPBMs.  The most relevant previous review included 26 papers [1].  The 
literature search reported here identified 43 papers published since this earlier review and 
included 17 additional papers, providing an up-to-date and comprehensive review of the 
literature in this area. 
A wide range of methods have been used at all stages of CSPBM development, within two 
overarching groups of approaches for construction of the classification system (derivation 
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from an existing instrument and de novo) and two for the estimation of the tariff (composite 
and decomposed methods).  The choice between developing a classification system de 
novo or from an existing instrument may depend largely on the availability of a suitable 
existing measure.  The choice between a decomposed or composite approach appears to be 
determined primarily by the purpose for which the instrument is designed (QALY generation 
or individual/ clinical level decision analysis), although considerations regarding the size of 
the classification system and practical constraints on the proportion of health states that can 
be valued directly may play a part.  More comparative studies are required to provide 
empirical evidence on the relative merits of these competing approaches.  Despite the recent 
publication of recommended methods for validation [1], uptake of these appears to have 
been relatively low, and this remains an area for further development. 
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Table 1: Outline of condition-specific preference-based measures 
First author(s) date Aim Condition HRQoL Dimensions States Country Scaling anchors 
Bellamy 1996 [10] NQM Peridontal disease Yes 4 320 UK Best state; pits 
Beusterien 2005 [11] QALY ALS No 4 750 USA Best state; dead 
Brazier 2005 [12] QALY Menopause No 7 6,075 UK Full health; dead 
Brazier 2008 [13] QALY Urinary tract symptoms Yes 5 1,024 UK Full health; dead 
Burr 2007 [14] NQM Glaucoma Yes 6 4,096 UK Best state; pits 
Chiou 2005 [15] QALY Asthma (paediatric) No 3 12 (10 valid) USA Unclear; dead 
Cho 2015 [16] QALY COPD No 3 12 (10 valid) South Korea Full health; dead 
Cuervo 2014 [17] UC Urinary No 5 243 UK Best state; dead 
Dobrez 2007 [18]; NQM Cancer Yes 4 48 USA Best state; dead 
validated by Hess 2013 [19]; Pickard 2012 
[20] 
      
Goodey 2000 [21] NQM Oral Yes 5 1,024 UK Best state; pits 
Goodwin 2015a [22]; Goodwin 2015ba [23] QALY Multiple sclerosis Yes 8 65,536 UK Full health; dead 
Gu 2013 [24] QALY Dupuytren’s contracture No 8 6,561 UK Best state; dead 
Hauber 2010 [25]; NQM Obesity Yes 8 6,561 USA Best state; pits re-modelled by Mohamed 2010 [26] 
Hodder 1997 [27] NQM Head and neck cancer Yes 8 390,625 UK Best state; pits 
Johnson 2006 [28]; Osoba 2006 [29]; NQM Cancer Yes 14 268,435,456 USA Best state; pits 
re-modelled by Mohamed 2010 [26]      
Kerr 2015 [30] QALY Aberrant behaviour in FXS No 5 2,187 UK Full health; dead 
Kind 2005 [31]; 
QALY Lung cancer Yes 
6 64 UK Full health; dead 
revalued by Lamers 2007 [32]; ʺ ʺ Netherlands Full health; dead 
validated by Pickard 2012 [20]      
Kok 2002 [33] QALY Urinary No 2 9 Netherlands Best state; dead 
Kowalski 2012 [34]; Rentz 2014 [35] 
validated by Naik 2013 [36] QALY Vision Yes 6 15,625 Multiple
b Full health; dead 
Krahn 2000 [37]; Ritvo 2005 [38]; 
NQM   Prostate cancer No 10 6,000,000 Canada Best state; dead Tomlinson 2012 [39]; translated and 
validated by Avila 2014 [40] 
Kuspinar 2014 [41] QALY Multiple sclerosis Yes 5 243 NA NA 
Lloyd 2014 [42] QALY Short bowel syndrome Yes 6 64 UK Full health; dead 
Martin 1999 [43], 1998 [44] NQM Cardiovascular Yes 4 268,880 Australia Best state; dead 
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Table 1 continued      
First author(s), date Aim Condition HRQoL Dimensions States Country Scaling anchors 
Mavranezouli 2011 [45]; 2013 [46] QALY Mental health Yes 6 729 UK Full health; dead 
McKenna 2008 [47] QALY Pulmonary hypertension Yes 4 36 UK Full health; dead 
Misajon 2005 [48]; Peacock 2008 [49]; 
QALY Vision Yes 6 45,360 Not stated Best state; dead validated by Finger 2013a [50], 2013b [51]; 
Gothwal 2013a [52], 2013b [53] 
Montejo 2011 [54] NQM Anti-psychotic side effects No 8 65,536 Spain Best state; dead 
Mulhern 2012a [55] QALY Epilepsy Yes 6 4,096 UK Full health; dead 
Mulhern 2012b [56]; 2013 [57]; Rowen 2012 
[58] QALY 
Dementia (proxy measure) Yes 5 1,024 UK Full health; dead 
Dementia (self-complete) No 4 256 UK Full health; dead 
Palmer 2000 [59] NQM Parkinson's disease No 2 10 USA Full health; dead 
Petrillo 2011 [60]; 2010c [61] QALY COPD No 5 UC UK Full health; dead 
Pickard 2009 [62] NQM Cancer Yes 5 144 USA Best state; dead 
Poissant 2003 [63] NQM Stroke Yes 10 59,049 Canada Best state; pits 
Ratcliffe 2009 [64] QALY Sexual quality of life Yes 3 64 UK Full health; dead 
Revicki 1998a [65]; 
NQM Asthma No 5 100,000
USA Best state; pits 
revalued by Flood 2006 [66]; Multipled Best state; pits 
validated by Bime 2012 [67]   
Revicki 1998b [68]; NQM Rhinitis No 5 100,000 USA Best state; pits revalued by Lo 2006 [69]  Hong Kong Best state; pits 
Revicki 2011 [70] NQM Acute rhinosinusitis Yes 5 1,024 USA Best state; pits 
Rowen 2011 [71]; 
QALY Cancer Yes 8 81,920
UK 
Best state; dead revalued by Kularatna 2015 [72] Sri Lanka 
validated by Rowen 2012 [73]  
Scholzel-Dorenbos 2012 [74] UC Dementia Yes 5 243 NA NA 
Shaw 1998 [75] NQM Menorrhagia No 6 4,096 UK Best state; pits 
Stevens 2005 [76] QALY Atopic dermatitis Yes 4 16 UK Full health; dead 
Stevens 2012 [77]; Palfreyman 2011e [78] QALY Venous ulcers Yes 5 720 UK Full health; dead 
Stolk 2003 [79] QALY Erectile function No 2 25 Netherlands Best state; dead 
Sundaram 2009 [80]; 2010 [81] QALY Diabetes No 5 768 USA Best state; dead 
Versteegh 2012 [82] 
QALY Arthritis No NA 1,024 Netherlands Best state; dead 
QALY Cancer Yes 8 65,536 Netherlands Best state; dead 
QALY Multiple sclerosis Yes NA 65,536 Netherlands Best state; dead 
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Table 1 continued      
First author(s), date Aim Condition HRQoL Dimensions States Country Scaling anchors 
Young 2009 [83]; Yang 2009 [84] 
validated by Desroziers 2013 [85] 
remodelled by Kharroubi 2014 [86] 
QALY Overactive bladder Yes 5 3,125 UK Best state; dead 
Young 2010 [87] QALY Flushing No 1 2,500 UK Full health; dead 
Young 2011 [88]; Yang 2011 [89]; 
QALY Asthma Yes 5 3,125 UK Best state; dead validated by McTaggart-Cowan 2008 [91] remodelled  by Kharroubi 2014 [86] 
rescaled by Hernandez-Alava, 2013 [90] 
a data provided by authors; b Rentz et al conducted four preference elicitation surveys, in Australia, Canada, the UK and the USA; c conference poster; d Flood et al 
conducted three preference elicitation surveys, in the UK, France and Italy; e newsletter article 
ALS = amyotrophic lateral sclerosis; FXS = fragile X syndrome; COPD = chronic obstructive pulmonary disease; QALY = instrument designed to generate QALY 
weights; NQM = instrument not designed to generate QALY weights; UC = unclear 
HRQoL: “No” indicates a classification system comprised of dimensions that describe specific symptoms rather than wider impacts on HRQoL; “Yes” indicates a 
classification system that includes one or more dimensions describing the impact of the condition on HRQoL.   
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Table 2: Methods for deriving classification systems from existing instruments 
 
Method of item selection:  Health state classification approach Other item selection method No items selected Unclear 
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Selecting an instrument                             
Wide usage X X X X X X X X    X  X X X  X  X X X   X   X 
Psychometric properties X X X X  X   X X X X X X X    X   X X   X X X 
Wide suitability X  X  X X   X             X X   X   
Importance to patients X            X X    X       X X X  
Other reason       X X          X   X     X  X 
Determining dimensions                             
Factor analysis X  X X X X X X X X X    X X     X   X  X   
Psychometric criteria  X X    X X  X  X   X      X X       
Rasch analysis  X    X                    X   
Expert opinion   X X  X      X    X          X   
Determined by item selection              X   X   X         
Original instrument developers                       X    X  
Conceptual framework X                            
Not reported       X X     X     X       X   X 
Item selection                             
Rasch criteria                             
Disordered thresholds X X X X X X X  X      X          
Differential item functioning X X X X X X X X X  X  X              
Item χ2  and/ or fit residuals X X X X X X X X X X X                  
Goodness of fit to Rasch model X X X X X X X X X X X  X                
Spread across latent space X X X X X X X X  X  X   X X          
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Table 2 continued          
  Health state classification approach Other item selection method No items selected Unclear 
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Psychometric criteria                             
Factor analysis    X X          X X X            
Missing data X X X X X X X X X X X X  X X  X  X  X        
Item response distributions X X X X X X X X X X X X  X X  X X   X        
Responsiveness   X X  X   X  X X                 
Internal consistency X  X   X X X X  X        X  X        
Construct validity            X  X    X X          
Other criteria                             
Expert opinion  X X X X X X X  X X  X  X X        
Item responses summed                        X X    
Levels created for 
dimensions 
                     X X   X   
Item selection not reported                           X X 
Item level reduction                             
Disordered thresholds X X X    X X  X    X       X        
Other Rasch analysis     X    X  X   X               
Item response distributions    X     X  X   X X            X  
Method not reported             X                
Validation                             
Repeat on different dataset X  X X  X   X  X                  
Separate survey                         X X   
Other methods   X  X        X                
Methods not specified                            X 
a includes two classification systems (DEMQOL and DEMQOL-proxy);  b arthritis measure;  c MS measure;  d cancer measure
Two studies obtained preference weights for an existing measure without alteration [Montejo et al, 2011; Revicki et al, 2011], and two provided no account of how a 
classification system was derived from the original measure [Beusterien et al, 2005; Ratcliffe et al, 2009]. 
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Table 3: Methods for developing a classification system de novo 
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Identifying dimensions                   
Qualitative work with patients X X   X X X X  X   X X X X  X 
Expert opinion   X X  X  X X  X  X X X    
Literature review  X  X    X   X  X X X    
Content of existing instruments  X X     X  X X    X    
Factor analysis          X         
Other statistical analysis        X X   X       
Determined by item selection         X        X  
Designing items                   
Qualitative work with patients   X     X  X   X X   X X 
Expert opinion   X     X     X X   X  
Literature review/ content of existing instruments   X      X  X X X X    X 
Traditional psychometric techniques          X  X     X X 
Rasch analysis or item response theory         X X       X X 
Other statistical analysis        X X   X      X 
Intra-domain statements X X  X X X X        X X   
Validation                   
Traditional psychometric analysis of validation survey            X   X    
Other statistical analysis of validation survey          X         
Other         X          
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Table 4: Summary of valuation and health state selection techniques 
First author, date Method for selecting health states No of states Technique Method Source Purpose 
Composite studies      
Brazier 2005 [12] Statistically efficient plus randomly selected states 96 TTO Interviews Patients QALY 
Brazier 2008 [13] Statistically efficient 49 SG Interviews Patients QALY 
Burr 2007 [14] Statistically efficient 32 pairs DCE Postal Patients NQM 
Cho 2015 [16] All health states valued by all respondents 10 TTO/ VAS Interviews Public QALY 
Goodwin 2015b [22] Rasch vignette plus patient feedback 169 TTO (MVH) Online Public QALY 
Gu 2013 [24] Statistically efficient 26 pairs DCE Not stated Public QALY 
Hauber 2010 [25] Statistically efficient 48 pairs DCE Online Patients NQM 
Johnson 2006 [28] Statistically efficient  72 pairs DCE Not stated Patients NQM 
Kerr 2015 [30] Statistically efficient 20 TTO Interviews Public QALY 
Kind 2005 [31] Statistically efficient  19 VAS Postal Public QALY 
Kok 2002 [33] All health states valued by all respondents TTO Interviews Public QALY 
Kularatna 2015 [72] Statistically efficient 85 TTO (MVH) Interviews Public QALY 
Lamers 2007 [32] Statistically efficient  19 VAS Online Public QALY 
Lloyd 2014 [42] Statistically efficient 16 LT-TTO Interviews Public QALY 
Mavranezouli 2013 [46] Rasch vignette approach 18 TTO (MVH) Interviews Public QALY 
McKenna 2008 [47] All health states valued by groups of respondents 36 TTO (MVH) Interviews Public QALY 
Mulhern 2013 (DEMQOL) [57] Statistically efficient  87 TTO (MVH) Interviews Public QALY 
Mulhern 2013 (proxy) [57] Statistically efficient  70 TTO (MVH) Interviews Public QALY 
Mulhern 2012 [55] Statistically efficient  50 TTO (MVH) Interviews Public QALY 
Palmer 2000 [59] All health states valued by all respondents VAS/ SG Interviews Patients NQM 
Petrillo 2011 [60] Statistically efficient plus frequently observed states 41 TTO (MVH) Interviews Public QALY 
Ratcliffe 2009 [64] 
All health states valued by groups of respondents 64 TTO (MVH) Interviews Public QALY 
All health states valued by groups of respondents 66 Ranking Interviews Public QALY 
Statistically efficient 12 pairs DCE Postal Public QALY 
Rentz 2014 [35] Unspecified selection method plus patient feedback 8 TTO Interviews Public QALY 
Rowen 2011 [71] Statistically efficient 85 TTO (MVH) Interviews Public QALY 
Stevens 2005 [76] All health states valued by all respondents SG Interviews Public QALY 
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Table 4 continued      
First author, date Method for selecting health states No of states Technique Method Source Purpose 
Palfreyman 2011 [78] Statistically efficient 26 TTO Interviews Public QALY 
Stolk 2003 [79] All health states valued by all respondents TTO Interviews Public QALY 
Versteegh 2012 (MS) [82] Statistically efficient plus frequently observed states 100 TTO CAPI Public QALY 
Versteegh 2012 (cancer) [82] Statistically efficient 105 TTO CAPI Public QALY 
Versteegh 2012 (arthritis) [82] Statistically efficient plus frequently observed states 56 TTO CAPI Public QALY 
Yang 2009 [84] Statistically efficient 99 TTO (MVH) Interviews Public QALY 
Young 2010 [87] Rasch vignette approach 16 TTO (MVH) Interviews Public QALY 
Yang 2011 [89] Statistically efficient 99 TTO (MVH) Interviews Public QALY 
Dobrez 2007 [18] Respondent’s own current health state  TTO Interviews Patients NQM 
Martin 1998 [44] Respondent’s own current health state  TTO, SG Interviews Patients NQM 
Pickard 2009 [62] Respondent’s own current health state  TTO Interviews Patients NQM 
Decomposed studies      
Bellamy 1996 [10] No health states valued: dimensions and levels valued separately RA, VAS Interviews Patients NQM 
Beusterien 2005 [11] VAS & SG: all 4 CS; 5 MA; perfect & normal health; dead. VAS: all SA VAS, SG  Online Public QALY 
Chiou 2005b [15] VAS & SG: CS (excluding one implausible); 1 MA; pits. VAS: all SA.  VAS, SG Interviews Public QALY 
Cuervo 2014 [17] VAS: all 5 CS; 3 MA; all SA; best state; pits; dead. TTO: 3 CS; 3 MA VAS, TTO Interviews Public UC 
Flood 2006 [66] VAS & SG: all 5 CS; 5 MA. VAS: all SA VAS, SG Interviews Patients NQM 
Goodey 2000 [21] No health states valued: dimensions and levels valued separately RA, VAS Interviews Patients NQM 
Hodder 1997 [27] No health states valued: dimensions and levels valued separately VAS NR Clinicians NQM 
Lo 2006 [69] VAS & SG: all 5 CS; 5 MA. VAS: all SA VAS, SG CAPI Patients NQM 
Montejo 2011 [54] VAS: all SA; all 8 CS; 2 MA; best state; pits. TTO: 2 CS; 2 MA VAS, TTO Interviews Patients NQM 
Peacock 2008 [49] TTO & RS: all 6 CS; pits. RS: all SA RS, TTO Interviews NS QALY 
Poissant 2003 [63] VAS: CS (excluding one implausible); best state; pits; dead; unconscious. No other preference elicitation technique used. VAS Interviews 
Patients, 
carers NQM 
Revicki 1998a [65] VAS & SG: all 5 CS; 5 MA. VAS: all SA VAS, SG Interviews Patients NQM 
Revicki 1998b [68] VAS & SG: all 5 CS; 5 MA. VAS: all SA VAS, SG Interviews Patients NQM 
Revicki 2011 [70] VAS & SG: all 5 CS; 5 MA. VAS: all SA VAS, SG Online Patients NQM 
Shaw 1998 [75] No health states valued: dimensions and levels valued separately RA, VAS Interviews Patients NQM 
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Table 4 continued      
First author, date Method for selecting health states Technique Method Source Purpose 
Sundaram 2010 [81] VAS & SG: 3 MA; pits; dead. VAS: 5 CS; 9 SA; best state VAS, SG Interviews Patients QALY 
Tomlinson 2012 [39] VAS: all 10 CS; 3 MA; dead; all SA. SG: 2 CS; 2 MA VAS, SG Interviews Patients NQM 
a conventional TTO for health states considered better than being dead; lead-time TTO for health states considered worse than being dead;  b All health 
states valued by all respondents 
TTO = time trade-off; LT-TTO = lead-time TTO; MVH = Measurement and Valuation of Health; SG = standard gamble; VAS = visual analogue scale; DCE = 
discrete choice experiment; RS = rating scale; RA = resource allocation task; CAPI = computer-assisted personal interview; QALY = instrument designed to 
generate QALY weights; NQM = instrument not designed to generate QALY weights; CS = corner states; MA = multi-attribute states; SA = single attribute 
states; pits = worst possible health state; NR = not reported; NA = not applicable 
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Table 5: Preferred models 
First author, year Model type Inconsistent coefficients 
Sig coefficients MAE Errors > 0.05 
Errors > 
0.10 R-squared RMSE p< 0.05 p< 0.1 
Brazier 2005 [12] OLS 2 - 33% 0.053 38% 16% 0.178g - 
Brazier 2008 [13] OLS Merged 27% 36% 0.018 2% 2% 0.32g - 
Burr 2007 [14] CLR Merged 100% 100% - - - 0.158h - 
Cho 2015 (TTO) [15] Mixed None 100% 100% 0.008 - - 0.86i - 
Dobrez 2007 [18] OLS Merged 57% 86% 0.19 - - 0.17 - 
Goodwin 2015b [23] RE None 83% 83% 0.041 31% 7% - - 
Gu 2013 [24] CLR None 100% 100% - - - - - 
Hauber 2010 [25] RE probit - - - - - - - - 
Johnson 2006 [28] RE probit - - - - - - - - 
Kerr 2015 [30] RE None 93% - 0.018 - - - - 
Kind 2005 A [31] OLS None - - - - - 0.443 - 
Kind 2005 B [31] OLS None - - - - - 0.413 - 
Kularatna 2015 [72] RE Merged 100% 100% - - - - - 
Lamers 2007 A [32] OLS None - - 0.029 - - 0.33 - 
Lamers 2007 B [32] OLS None - - 0.043 - - 0.29 - 
Lloyd 2014 [42] RE None 100% 100% 0.045 - - - 0.063 
Martin 1998 [44] Other - - - - - - 0.42 - 
Mavranezouli 2013 [46] Rasch OLS - 80% 100% - - - 0.99g 0.028 
McKenna 2008 [47] OLS None 100% 100% 0.041 35% 6% 0.936g - 
Mulhern 2012 [55] RE Merged 65% 77% 0.065 44% 14% 0.293g 0.052 
Mulhern 2013a [57] RE Merged 73% 80% 0.045 35% 8% - 0.060 
Mulhern 2013b [57] RE Merged 82% 100% 0.042 36% 9% - 0.057 
Petrillo 2011 [60] FE Merged 80% - 0.039 15% 2% - 0.054 
Pickard 2009 [62] Other Merged 44% - - - - 0.082h - 
Ratcliffe (TTO) [64] OLS 2 56% - 0.040 31% None 0.517g - 
Ratcliffe (TTO) [64] RE None 78% - 0.072 23% 2% 0.207g - 
Ratcliffe (DCE) [64] RE probit 1 56% - 0.077 38% 5% 0.203g - 
Ratcliffe (rank) [64] Logit 1 78% - 0.069 28% 6% 0.198g - 
Ratcliffe (rank) [64] Rescaled logit 1 78% - 0.083 69% 36% 0.198g - 
Rentz 2014 [35] Rasch OLS None 100% 100% - - - 0.418g - 
Rowen 2011 [71] OLS (ERUM) 2 88% - 0.046 39% 7% 0.56 - 
Versteegh 2012c [82] RE None 100% - 0.040 - - 0.78 - 
Versteegh 2012d [82] RE None 100% - 0.033 - - 0.88 - 
Versteegh 2012e [82] RE None 100% - 0.028 - - 0.94 - 
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Table 5 continued         
First author, year Model type Inconsistent coefficients 
Sig coefficients MAE Errors > 0.05 
Errors > 
0.10 R-squared RMSE p< 0.05 p< 0.1 
Yang 2009 [84] OLS Merged 67% - 0.045 40% 6% - - 
Yang 2011 [89] OLS Merged 65% - 0.048 32% 9% 0.957 0.046 
Young, 2010 [87] Rasch OLS - 100%f - - - 0.958 0.042 
a DEMQOL-U;  b DEMQOL-U-proxy; c MS-PBM;  d QLQ-PBM;  e HAQ-PBM; f p-value not stated;  g adjusted R-squared; h pseudo R-squared; i generalised 
R-squared 
No modelling: Kok 2002 [33]; Palmer 2000 [59]; Stevens 2005 [76]; Stolk 2003 [79].  No report of model performance: Palfreyman, 2010 [78]. 
MAE = mean absolute error;  RMSE = root mean squared error; OLS = ordinary least squares; CLR = conditional logistic regression; mixed = model 
incorporating fixed and random effects; RE = random effects; FE = fixed effects; ERUM = episodic random utility model 
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Table 6: Validation of condition-specific preference-based measures 
Test Convergent validity Discriminative validity Responsiveness 
Comparator measure Parent GPBM Other Map Values Parent GPBM Other Map NC Parent GPBM Other Map NC 
Beusterien 2005 [11]     X           
Brazier 2008 [13]           X     
Burr 2007 [14]  X X             
Chiou 2005 [15]  X   X     X      
Cuervo 2014 [17]     X           
Dobrez 2007 [18]     X     X      
Flood 2006 [66]   X       X      
Goodwin 2015b [23] X X    X X    X X    
Kharroubi 2014 [86]     X           
Kok 2002 [33]     X           
Lamers 2007 [32]          X     X 
Lo 2006 [69]   X       X      
McKenna 2008 [47] X      X         
Montejo 2011 [54]  X X             
Mulhern 2013 [57] X X X       X     X 
Palmer 2000 [59]   X       X      
Petrillo 2011 [60]     X     X     X 
Poissant 2003 [63]   X       X  X    
Rentz 2014 [35] X         X      
Revicki 1998a [65]  X X       X      
Revicki 1998b [68]  X X       X      
Revicki 2011 [70]   X       X     X 
Sundaram 2010 [81]   X  X     X      
Tomlinson 2012 [39]     X           
Versteegh 2012 [82]  X     X        X 
Retrospective validations {original papers} 
Avila 2014 [40] {39}      X          
Bime 2012 [67] {65}   X            X 
Brazier 2012 [1] {46; 71; 84; 
89}  
X X    X X    X X    
Desroziers 2013 [85] {84}  X          X    
Gothwal 2013b [53] {49}     X   X        
Hess 2013 [19] {16}   X X    X X    X X  
Finger 2013b [51] {49}       X         
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Table 6 continued    
Test Convergent validity Discriminative validity Responsiveness 
Comparator measure Parent GPBM Other Map Values Parent GPBM Other Map NC Parent GPBM Other Map NC 
McTaggart-Cowan 2008 [91] 
{89}  
X X X   X X X        
Naik 2013 [36] {35}  X    X     X     
Pickard 2012 [20] {18; 31}   X X X   X  X       
Rowen 2012b [73] {71}  X X  X  X X  X  X X  X  
Parent = measure from which classification system was derived; GPBM = generic preference-based measure; values = directly elicited HSUVs; map = mapping algorithm 
from parent measure to EQ-5D; NC = no comparator 
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Supplementary material 
Literature search strategy 
Search terms Hits 2011 Hits 2013 Hits 2015
1. “quality of life”/ 
2. quality of life.mp 
3. qol.mp 
4. hrqol.mp 
5. hrql.mp 
6. health status/ 
7. health status.mp 
8. quality adjusted life year/ 
9. quality adjusted life year$.mp  
10. qaly$.mp 
166328
203988
18459
5882
2173
63583
77473
7309
8691
4432
223308 
276051 
28351 
9378 
3004 
78316 
96043 
10733 
12696 
7587 
289794
354960
40268
13671
3812
93296
115196
14342
16536
10705
11. develop$.mp 
12. deriv$.mp 
13. estimat$.mp 
14. creat$.mp 
15. generat$.mp 
16. construct$.mp 
17. valu$.mp 
18. transform$.mp 
19. transfer$.mp 
20. translat$.mp 
21. conver$.mp 
22. map$.mp 
2850491
1984064
597063
386614
638314
295607
1415469
356439
486773
157242
369549
328352
3523944 
2331151 
757811 
496471 
806968 
362776 
1727519 
431408 
586677 
208766 
453000 
408076 
4249388
2600597
948382
624253
984354
435422
2120858
517037
691188
263142
545448
473423
23. preference base$.mp 
24. utilit$.mp 
25. preference weight$.mp 
26. valuation weight$.mp 
27. preference valu$.mp 
28. qaly weight$.mp 
29. health state$ 
30. valu$ 
31. preference$ 
32. rank$  
33. 30 OR 31 OR 32  
34. (health state$ ADJ5 (valu$ OR preference$ OR rank$)).mp 
556
109102
147
2
113
28
3505
1415469
86019
94243
1566231
796
824 
144102 
239 
3 
147 
40 
5013 
1727519 
109509 
131160 
1927111 
1134 
1117
182591
319
4
181
53
6681
2120858
136584
179437
2380666
1409
35. instrument$.mp 
36. measure$.mp 
37. classification system$.mp 
38. health state classification$.mp 
39. descriptive system$.mp 
40. index.mp 
41. indices.mp 
42. indexes.mp 
43. “quality of life index”/ 
44. tool$.mp 
45. questionnaire/ OR structured questionnaire/  
46. questionnaire$.mp 
47. scale$.mp 
48. rating scale/ 
409212
2072299
12404
52
135
414191
95349
25599
799
336360
274878
367011
441790
67425
487262 
2548309 
16542 
72 
195 
553790 
115862 
31604 
1361 
457131 
360022 
480246 
588311 
78984 
526455
3096367
21106
91
279
730951
141360
38698
1931
597143
454615
610647
769671
91093
Table continues overleaf
Search terms Hits 2011 Hits 2013 Hits 2015 
49. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 
50. 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18  
      OR 19 OR 20 OR 21 OR 22 
51. 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 34 
52. 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42  
      OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 
53. 49 AND 50 AND 51 AND 52 
269913
7423215
109791
3441043
3431
357153 
8986145 
 
145010 
4294449 
 
6888 
452503
10649837
183761
5251866
9283
54. LIMIT 53 to English language 
55. LIMIT 54 to yr=”2011 –Current” 
55. LIMIT 54 to yr=”2013 –Current” 
6672 
2100 
 
9042
2761
 
 
Please note: The search strategy also includes terms to identify mapping studies, to 
contribute to other research projects. 
Databases searched: Embase; Medline (R); Medline (R) In-Process and Other Non-
Indexed Citations; PsycINFO; Web of Science (Science Citation Index, Social 
Sciences Citation Index, Conference Proceedings Citation Index – Science, 
Conference Proceedings Citation Index – Social Science and Humanities); the 
Cochrane Library (Cochrane reviews, other reviews, clinical trials, methods studies, 
technology assessments and economic evaluations); CINAHL; EconLit; ASSIA; and 
the Health Management Information Consortium (HMIC) database.  In addition, 
citation searching, a Google search and searches of the Discussion Papers 
published on the Sheffield School of Health and Related Research (ScHARR) Health 
Economics and Decision Science website were undertaken. 
 
  
Data extraction form 
Basic details 
1st author:  Year:  
Condition:  
Non-PBM / de novo:  
New PBM name:  
Citation:  
Article coverage:  Brazier review? Y/N 
Classification system 
Original instrument: Dimensions: Items:  Levels:  
New instrument: Dimensions: Items:   Levels:  States:  
Rationale for choosing 
instrument: 
 
Dimensions of new 
instrument: 
 
Dimensionality design 
methods: 
 
Item reduction/ 
selection methods: 
 
Level reduction/ 
selection methods: 
 
Dataset used: Sample size:  Population:  
Classification system 
validation: 
 
Additional notes:  
Valuation methods 
Health state selection 
method: 
 
States per respondent:  
Total no states valued:  No per respondent:  
Valuation source: Patient/public Country:  
Sample size:  No of respondents:  
Respondents 
excluded: 
 
Valuation technique: eg TTO 
Valuation method: eg interview Condition label:  
Rationale for choice of 
technique: 
 
States worse than 
dead: 
 
Upper anchor:  Lower anchor:  
Additional notes:  
  
Modelling 
Modelling approach: Decomposed / 
statistical 
Chosen model 
type: 
Additive/ 
multiplicative etc 
Chosen model level: Individual/ 
aggregate 
Constant:  
Preference 
interactions: 
 
Transformations: For statistical approach, did they adjust for skewness, 
truncation and non-continuity of data? 
VAS to SG conversion: If VAS was used, how was this converted to SG? 
Models tested: Particularly if individual OLS model selected, were RE 
and mean level models considered? 
Rationale for selecting 
preferred model: 
 
Preferred model 
specification: 
 
Respondent 
characteristics: 
Were any significant differences found between groups 
of respondents? 
Additional notes:  
Model performance 
Mean absolute error  MAE 95% CIs  
No of errors > 0.05  No of errors > 0.10  
Root mean sq. error  Mean error  
R-squared  Adj R-squared  
Max predicted score 
compared to obs 
 Min predicted score 
compared to obs 
 
Proportion of 
coefficients p<0.05 
 Proportion of 
coefficients p<0.1 
 
Coefficients with 
unexpected sign 
 Inconsistent 
coefficients 
 
Other goodness of fit 
measures 
Eg t-test and the normality of prediction errors (eg the 
Jarque-Bera test) to assess bias in predictions; testing of 
MAUT models 
Additional notes:  
Validation of overall instrument 
Acceptability:  
Reliability:  
Validity:  
Responsiveness:  
Other notes on 
quality: 
 
Any other notes 
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